I
f we live well, eat right, do not smoke, and by so doing avoid the usual diseases that end life prematurely, we will get old. More of us are doing so every year. Thus, for selfish and scientific reasons, the physical, biochemical, and molecular changes provoked by aging merit attention. A revolution in our understanding of how noncoding ribonucleic acid (RNA) species regulate cardiovascular function in health and disease makes the intersection between microribonucleic acid (miRNA) biology and aging fertile ground for investigation. In this issue of the Journal, Gupta et al.
(1) described a miRNA that is increased in aging and suppresses a process whose dysfunction is postulated to contribute to aging phenotypes, autophagy.
Autophagy ("self-eating") is an adaptive response to starvation and a compensatory response that promotes cell and tissue renewal in disease. However, autophagic activity decreases with age, and interruption of autophagy mimics aging, suggesting a pathophysiological relationship (2). Gupta et al. (1) developed and applied a screening system that identified miR-22 as a potent inhibitor of cardiac autophagy. They further discovered that miR-22 was increased in abundance in older mouse hearts, higher circulating levels of miR-22 were associated with adverse outcomes in clinical heart failure, and miR-22 inhibition using a specific anti-microribonucleic acid (anti-miR) enhanced cardiac autophagy and 
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include cardiac growth and development (9), cardiomyocyte apoptosis (10), myocardial fibrosis (11), and cardiac hypertrophy (3), to which we can now add autophagy (1).
Although a particular miRNA-mRNA interaction typically suppresses protein levels by only about onehalf, this effect can be increased by the combined actions of several coregulated miRNAs that target the same mRNA. Moreover, miRNAs classically target multiple mRNA-encoded proteins within the same biological pathway, multiplying the overall effect due to serial suppression (50% Â 50% Â 50%, and so on).
For these reasons, miRNA inhibition with anti-miRs is undergoing preclinical evaluation in a number of clinically relevant cardiac conditions: anti-miR-208a
is being investigated to alleviate cardiac remodeling during heart failure in hypertensive rats (12) gdorn@wustl.edu.
